Pesquisas alternativas:
dermato venereologie » dermato venereology (Expandir a Pesquisa), _ dermatovenereologic (Expandir a Pesquisa), dermatovenereology _ (Expandir a Pesquisa)
dermatol venereol » dermato venereology (Expandir a Pesquisa)
eur acad » nur acar (Expandir a Pesquisa), eur ace (Expandir a Pesquisa)
j eur » j eum (Expandir a Pesquisa), _ eur (Expandir a Pesquisa), j ebr (Expandir a Pesquisa)
venereologica » venereologia (Expandir a Pesquisa), venereology (Expandir a Pesquisa), venerologii (Expandir a Pesquisa)
A mostrar 1 - 20 resultados de 119 para a pesquisa 'j eur acad ((dermatol venereol) OR (((dermato venereologie) OR (dermato venereologica))))', tempo de pesquisa: 1.36seg Refinar resultados
Head-to-head trials of systemic psoriasis therapies: A systematic review of study design and maximum acceptable treatment differences.
Real‐life effectiveness of once‐daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: final analysis of the 52‐week PRO‐long study

Measurement of Tanning Dependence
Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study

Increased prevalence of HCV and hepatic decompensation in adults with psoriasis: a population-based study in the United Kingdom
The role of IL‐23 and the IL‐23/T(H)17 immune axis in the pathogenesis and treatment of psoriasis

Initiation of TNF Inhibitor Therapy and Change in Physiologic Measures in Psoriasis
The three moments of skin cream application: an evidence‐based proposal for use of skin creams in the prevention of irritant contact dermatitis in the workplace

Granuloma annulare associated with immune checkpoint inhibitors
The Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI): grading disease severity and assessing responsiveness to clinical change in epidermolysis bullosa

Treatment outcomes with ixekizumab in patients with moderate‐to‐severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies
A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE)

Shifting the focus – the primary role of IL‐23 in psoriasis and other inflammatory disorders
Efficacy and safety of adalimumab in Chinese patients with moderate‐to‐severe plaque psoriasis: results from a phase 3, randomized, placebo‐controlled, double‐blind study

Depression and the risk of psoriasis in US women
A patient‐centred approach to biological treatment decision making for psoriasis: an expert consensus

Public primary and secondary skin cancer prevention, perceptions and knowledge: an international cross‐sectional survey
Improvements in patient‐reported outcomes in patients with psoriasis receiving etanercept plus topical therapies: results from REFINE

The efficacy and safety of apremilast, etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from a phase IIIb, randomized, placebo‐controlled trial (LIBERATE)
Host risk factors for the development of multiple non-melanoma skin cancers

Ferramentas de pesquisa: Obter Feed RSS — Enviar pesquisa por email — Guardar a pesquisa